April 2020: The German Federal Institute for Drugs and Medical Devices(Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) has authorized the execution of our study: “A multicentric, single arm, prospective, stratified clinical investigation to evaluate the ability of MammoWave in breast lesions detection”
April 2020: The German Federal Institute for Drugs and Medical Devices(Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) has authorized the execution of our study: “A multicentric, single arm, prospective, stratified clinical investigation to evaluate the ability of MammoWave in breast lesions detection” Thanks to the BfArM authorization, we can continue our path towards the execution of MammoWave clinical trails also in Germany.